Difference between revisions of "Team:Amoy/Notebook"
ShannonLee (Talk | contribs) |
ShannonLee (Talk | contribs) |
||
| Line 87: | Line 87: | ||
<li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging'>Judging</a> | <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging'>Judging</a> | ||
<ul> | <ul> | ||
| − | <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging | + | <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging/Medal'>Medal Criteria</a></li> |
| − | <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging | + | <li class='has-sub'><a href='https://2015.igem.org/Team:Amoy/Judging/Acknowledgement'>Acknowledgement</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
Revision as of 17:09, 6 September 2015
NOTEBOOK
Document the dates you worked on your project. Initially, they used isolated enzymes, which can be disadvantageous for the reason that enzymes are always destabilized in the isolation and purification process. What's more, the cofactor-NADH is rather an expensive raw material, which will enhance the cost of L-tert-leucine production. So scientists introduced whole-cell biocatalysts to L-tert-leucine production. Whole-cell biocatalysts could stabilize enzymes and reduce the addition level of cofactor NADH.
What should this page have?
·Chronological notes of what your team is doing. ·Brief descriptions of daily important events. ·Pictures of your progress. ·Mention who participated in what task. Inspiration
You can see what others teams have done to organize their notes: 2014 ATOMS-Turkiye 2014 Tec Monterrey 2014 Kyoto 2014 Cornell
CONTACT US
Email: igemxmu@gmail.com
Website: 2015.igem.org/Team:Amoy
Address: Xiamen University, No. 422, Siming South Road, Xiamen, Fujian, P.R.China 361005
